<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute myeloid leukemia: Molecular genetics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute myeloid leukemia: Molecular genetics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute myeloid leukemia: Molecular genetics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wendy Stock, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Thirman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate into mature hematopoietic cells (ie, neutrophils).
        </p>
        <p>
         Similar to other malignancies, the genetic alterations in AML include mutation of oncogenes as well as the loss of tumor suppressor genes. In contrast to most solid tumors, many hematologic malignancies are associated with a single characteristic cytogenetic abnormality (eg, the Philadelphia chromosome [t(9;22)] in chronic myeloid leukemia and t(15;17) in acute promyelocytic leukemia).
        </p>
        <p>
         Advances in the identification of recurring chromosomal abnormalities and translocations have provided major insight into the pathobiology of AML. (See
         <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">
          "Tools for genetics and genomics: Cytogenetics and molecular genetics"
         </a>
         .)
        </p>
        <p>
         Specific cytogenetic abnormalities identified by karyotype analysis have considerable prognostic significance for patients with AML and affect treatment planning  (
         <a class="graphic graphic_table graphicRef80216" href="/z/d/graphic/80216.html" rel="external">
          table 1
         </a>
         ). Abnormalities in certain genes (eg, mutations in
         <em>
          FLT3
         </em>
         ,
         <em>
          nucleophosmin
         </em>
         ,
         <em>
          KIT
         </em>
         ) as well as gene expression profiles confer prognostic significance in adult patients with AML. Even those patients without obvious abnormalities detected by karyotypic analysis or gene expression profiles have acquired copy number alterations that may help to identify genes important for the pathogenesis of AML [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p>
         The focus of this topic review will be on the various molecular genetic events involved in the pathogenesis of AML. More general discussions of genetic events in hematologic malignancies are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4500.html" rel="external">
          "Genetic abnormalities in hematologic and lymphoid malignancies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">
          "General aspects of cytogenetic analysis in hematologic malignancies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H91419583">
         <span class="h1">
          GENE MUTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gene sequencing studies have shown that, on average, de novo AML cases contain more than 10 significant gene mutations, many of which can be broadly grouped into nine categories of genes thought to participate in leukemogenesis: DNA methylation, tumor suppressors, transcription factor fusions, nucleophosmin, signaling molecules, chromatin modification, myeloid transcription factors, the cohesin complex, and the spliceosome complex [
         <a href="#rid3">
          3
         </a>
         ]. The most common genes mutated are:
         <em>
          FLT3
         </em>
         (28 percent),
         <em>
          NPM1
         </em>
         (27 percent), DNMT3A (26 percent),
         <em>
          IDH1
         </em>
         or
         <em>
          IDH2
         </em>
         (20 percent),
         <em>
          NRAS
         </em>
         or
         <em>
          KRAS
         </em>
         (12 percent),
         <em>
          RUNX1
         </em>
         (10 percent),
         <em>
          TET2
         </em>
         (8 percent),
         <em>
          TP53
         </em>
         (8 percent),
         <em>
          CEBPA
         </em>
         (6 percent), and
         <em>
          WT1
         </em>
         (6 percent).
        </p>
        <p>
         The nature of the genetic lesions that are required to establish AML is not well defined, but the combination of mutations in any given AML is not random [
         <a href="#rid4">
          4,5
         </a>
         ]. As examples, mutations in genes that encode signaling molecules (eg,
         <em>
          FLT3, RAS
         </em>
         ) often accompany chromosomal rearrangements that target hematopoietic transcription factors (eg,
         <em>
          PML-RARalpha
         </em>
         ,
         <em>
          CBFbeta-MYH11
         </em>
         ) or key hematopoietic transcription factors (eg,
         <em>
          CEBPA, RUNX1
         </em>
         ). Conversely, mutations of genes in a single physiologic pathway are often mutually exclusive; as an example, it is uncommon to find mutations of more than one gene that regulates DNA demethylation (eg,
         <em>
          TET2, IDH
         </em>
         ) in a given AML sample.
        </p>
        <p>
         The pathogenetic effects of some of these mutations will be discussed here. The prognostic value of gene mutations in patients with AML is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24780405">
         <span class="h2">
          Mutations affecting DNA methylation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gene mutations that affect DNA methylation have been identified in patients with AML. These mutations may result in the expression of genes that are normally silenced or in the silencing of genes that are normally expressed. DNA methylation patterns may also have prognostic significance [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         DNA methylation involves the addition of a methyl group to cytosine or adenine residues within DNA. Hypermethylated genes are generally not expressed (ie, silenced); as such, DNA methylation provides an epigenetic method for altering gene expression. This process is an essential component of normal development and cell differentiation, and alterations in DNA methylation may impair cell differentiation, as is seen in AML [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Mutations associated with AML are found in genes that encode enzymes involved in both DNA methylation (eg,
         <em>
          DNMTs
         </em>
         ) and DNA demethylation (eg,
         <em>
          IDH, WT1, TET2
         </em>
         ). Deregulation of the IDH/WT1/TET2 axis is seen in as many as one-third of patients with AML, but mutations in genes associated with DNA demethylation are usually mutually exclusive in a given AML sample. The critical downstream targets of these changes in DNA methylation have not yet been identified.
        </p>
        <p class="headingAnchor" id="H17582181">
         <span class="h3">
          DNMT mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         DNA methyltransferases (DNMTs) are enzymes responsible for initiating and/or maintaining DNA methylation in mammalian cells. Without DNMTs, cells would gradually lose methyl groups from their DNA, leading to the expression of genes that are usually silenced. In one study,
         <em>
          DNMT3A
         </em>
         mutations were found in 22 percent of 281 patients with de novo AML [
         <a href="#rid8">
          8
         </a>
         ]. When compared with patients without such mutations, patients with
         <em>
          DNMT3A
         </em>
         mutations had a significantly shorter median survival (12 versus 41 months). Another DNA sequencing study suggested that the rate of
         <em>
          DNMT3A
         </em>
         mutations varies by AML subtype, with the highest rate (20 percent) seen among cases of acute monocytic leukemia (ie, FAB M5) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17582194">
         <span class="h3">
          TET mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          TET
         </em>
         (ten-eleven translocation) genes encode proteins with enzymatic activity that initiate the multistep process of DNA demethylation [
         <a href="#rid10">
          10
         </a>
         ]. Somatic mutations in
         <em>
          TET2
         </em>
         occur in approximately 15 percent of myeloid cancers, including AML [
         <a href="#rid11">
          11
         </a>
         ]. Mutations of
         <em>
          TET2
         </em>
         result in increased methylation and silencing of genes that are normally expressed. In mice, ablation of TET2 alters the function of hematopoietic stem cells and induces myeloid leukemia [
         <a href="#rid12">
          12
         </a>
         ]. WT1 (Wilms tumor 1) is an interaction partner of TET2, and regulates TET2 binding to DNA, thereby providing another mechanism that can alter DNA methylation [
         <a href="#rid13">
          13,14
         </a>
         ]. (See
         <a class="local">
          'Tumor suppressor genes'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2838486764">
         <span class="h3">
          IDH mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         IDH (isocitrate dehydrogenase) enzymes catalyze the conversion of isocitrate to alpha-ketoglutarate. Mutated IDH enzymes generate the "oncometabolite" 2-hydroxyglutarate, which inhibits TET2 function. Mutations of
         <em>
          IDH1
         </em>
         and
         <em>
          IDH2
         </em>
         are found in approximately 7 and 9 percent, respectively, of patients with AML, and are generally found in AML with a normal karyotype [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'IDH1'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1010111556">
         <span class="h3">
          ASXL mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The function of ASXL (additional sex combs-like) proteins is poorly understood, but they may act as epigenetic regulators by serving as scaffolds for transcription activators, repressors, and related proteins [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'ASXL1'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Tumor suppressor genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormalities of several tumor suppressor genes have been well characterized in myeloid leukemias. These are described in the following sections.
        </p>
        <p class="headingAnchor" id="H3834322599">
         <span class="h3">
          TP53 mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progression to blast crisis in CML is commonly associated with acquisition of mutations in
         <em>
          TP53
         </em>
         [
         <a href="#rid18">
          18-20
         </a>
         ]. In AML, only approximately 7 percent of cases have known
         <em>
          TP53
         </em>
         mutations at the time of diagnosis, although the incidence of
         <em>
          TP53
         </em>
         abnormalities may be higher in patients with AML evolving from a prior myelodysplastic syndrome (MDS) [
         <a href="#rid21">
          21
         </a>
         ], in AML associated with 11q23 translocations [
         <a href="#rid22">
          22,23
         </a>
         ], and in AML with complex karyotype [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4487.html" rel="external">
          "Cellular and molecular biology of chronic myeloid leukemia", section on 'Progression to acute phase CML'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'TP53'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H229049107">
         <span class="h3">
          WT1 mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Wilms tumor suppressor gene (
         <em>
          WT1
         </em>
         ) is overexpressed in the leukemic blasts of approximately 75 percent of cases of newly diagnosed AML [
         <a href="#rid25">
          25,26
         </a>
         ]. The
         <em>
          WT1
         </em>
         gene, located at chromosome 11p13, encodes a transcription factor expressed mainly in kidneys and gonads [
         <a href="#rid27">
          27,28
         </a>
         ], but it is also expressed in normal CD34+/CD38– hematopoietic progenitor cells [
         <a href="#rid29">
          29
         </a>
         ]. In AML, high
         <em>
          WT1
         </em>
         levels at diagnosis have, in some studies, been shown to correlate with lower remission rates and overall survival [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2695955234">
         <span class="h3">
          NF1 mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with neurofibromatosis and mutations of the
         <em>
          NF1
         </em>
         tumor suppressor gene have a high rate of developing neoplasms, including progression of MDS into AML [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1988586120">
         <span class="h3">
          Other tumor suppressor mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some tumor suppressors that are commonly associated with other malignancies (eg, lymphomas) are infrequently found in AML, whereas certain as-yet-unidentified regulators may be located at chromosomal regions that are frequently deleted in AML.
        </p>
        <p>
         Examples include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          INK4
         </em>
         (ie, p16) is a cyclin dependent kinase inhibitor that is frequently deleted in acute lymphoblastic leukemia, but is only very rarely mutated in AML [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         BCL-2 (B cell leukemia/lymphoma-2) is overexpressed in a wide variety of lymphoid malignancies as a result of t(14;18), which juxtaposes
         <em>
          BCL-2
         </em>
         with the Ig heavy chain locus. BCL-2 overexpression in AML has been reported only rarely, but in a study of patients with newly diagnosed AML, a multivariate analysis showed that BCL-2 overexpression was associated with lower complete remission rates and a significantly shorter survival [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">
          "Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Cytogenetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain chromosomal deletions are closely associated with AML (eg, loss of the long arms of chromosomes 5, 7, and 20). These abnormalities occur commonly in therapy-related AML and AML associated with prior MDS, and are associated with a poor prognosis  (
         <a class="graphic graphic_table graphicRef60295" href="/z/d/graphic/60295.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid34">
          34-36
         </a>
         ]. The involved genes have not yet been identified, although novel tumor suppressor genes or other regulatory molecules are likely to be encoded at these loci.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17582233">
         <span class="h2">
          Activated signaling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations impacting signal activation are seen in approximately 60 percent of AML cases and include point mutations in
         <em>
          FLT3, KIT
         </em>
         , other tyrosine kinases, serine-threonine kinases,
         <em>
          KRAS/NRAS
         </em>
         , or protein-tyrosine phosphatases [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17582247">
         <span class="h3">
          FLT3
         </span>
         <span class="headingEndMark">
          —
         </span>
         FLT3 is a transmembrane tyrosine kinase receptor that stimulates cell proliferation upon activation. Mutations in the FMS-like tyrosine kinase 3 gene producing internal transmembrane duplications (FLT3/ITD) and constitutive activation of the FLT3 receptor tyrosine kinase are quite common in AML, particularly in patients with normal karyotypes.
        </p>
        <p>
         There are two main types of
         <em>
          FLT3
         </em>
         mutations. The most common are internal tandem duplications of different length that result in ligand-independent activation of the FLT3 receptor and a proliferative signal. Alternatively, point mutations in the activating loop of the kinase domain of FLT3 may result in tyrosine kinase activation of FLT3 in 5 to 10 percent of patients [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         The prognostic impact of
         <em>
          FLT3
         </em>
         mutations is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'FLT3'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          RAS oncogene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations of three closely related
         <em>
          RAS
         </em>
         (
         <em>
          HRAS, KRAS, NRAS
         </em>
         ) proto-oncogenes occur in human malignancies. Each of these genes encodes a structurally similar 21 kilodalton protein which localizes to the inner plasma membrane and plays an important role in signal transduction [
         <a href="#rid39">
          39
         </a>
         ]. Specific point mutations occur characteristically in each of the three genes, although no consistent karyotypic abnormalities have been associated with RAS mutation and activation [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Mutations of
         <em>
          RAS
         </em>
         have been identified in approximately 25 percent of cases of AML [
         <a href="#rid40">
          40,41
         </a>
         ], and are observed with higher frequency in MDS (35 percent) [
         <a href="#rid42">
          42,43
         </a>
         ]. The majority of the mutations in AML and MDS are in the
         <em>
          NRAS
         </em>
         gene;
         <em>
          KRAS
         </em>
         and
         <em>
          HRAS
         </em>
         mutations occur less frequently. In both AML and MDS,
         <em>
          RAS
         </em>
         mutations have been reported more frequently in cases with a monocytic morphology (eg, FAB M4 and chronic myelomonocytic leukemia) [
         <a href="#rid44">
          44
         </a>
         ]. An association between AML in patients with a variety of occupational exposures and RAS mutations has also been observed [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         The significance of
         <em>
          RAS
         </em>
         mutations in AML remains unclear. RAS mutations have been reported at diagnosis, but not at relapse in some AML cases [
         <a href="#rid46">
          46
         </a>
         ]. Conversely,
         <em>
          RAS
         </em>
         mutations have been acquired at the time of relapse or disease progression [
         <a href="#rid44">
          44,47
         </a>
         ]. However, the presence of RAS mutations has been associated with improved survival [
         <a href="#rid41">
          41
         </a>
         ], possibly related to a lower leukemic cell burden at presentation, or an increased sensitivity to chemotherapy with
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17582339">
         <span class="h2">
          NPM1 mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nucleophosmin (NPM1) is a ubiquitously-expressed phosphoprotein involved in ribosomal protein assembly and transport and regulation the tumor suppressor ARF (cyclin-dependent kinase inhibitor 2A). NPM1 shuttles between the nucleus and cytoplasm, but mutations associated with AML (typically four base pair insertions that cause a frameshift) eliminate the C-terminus amino acids responsible for nucleolar localization; as a result, mutant NPM1 is retained in the cytoplasm [
         <a href="#rid49">
          49,50
         </a>
         ]. HOXA and HOX B cluster genes are consistently overexpressed in
         <em>
          NPM1
         </em>
         -mutated AML.
        </p>
        <p>
         <em>
          NPM1
         </em>
         mutations are associated with improved outcomes in younger and older adults and in children with AML, although the mechanism for increased chemosensitivity is not known. The prognostic impact of NPM1 mutations in AML is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'NPM1'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2412567570">
         <span class="h2">
          Splicing factor mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mutations involving the mRNA assembly system that cause aberrant mRNA splicing are highly specific to myeloid diseases that exhibit dysplastic features.
        </p>
        <p>
         Splicing factor mutations are found in 85 percent of MDS with increased ring sideroblasts; 45 percent of MDS without increased ring sideroblasts; 55 percent of chronic myelomonocytic leukemia (CMML); and in 25 percent of secondary AML, therapy-related myeloid neoplasms (t-MN), or AML with myelodysplasia-related changes; these mutations are rare in de novo AML (5 to 10 percent) [
         <a href="#rid51">
          51
         </a>
         ]. These mutations affect a number of genes that are components of the pre–messenger RNA splicing machinery including
         <em>
          SF3B1, SRSF2, U2AF1, U2AF35, ZRSR2, U2AF65, SF1, SF3A1
         </em>
         , and
         <em>
          PRPF40B
         </em>
         and have, in several studies, been shown to mirror the clinical course of patients with secondary AML or t-MN (eg, inferior response to standard induction chemotherapy).
        </p>
        <p>
         Distinct molecular subsets with specific alternative spliced isoforms of genes that are involved in innate immune and NF-kB signaling; these findings may provide insight into AML pathogenesis and provide therapeutic targets. As an example,
         <em>
          IRAK4-L
         </em>
         was the dominant isoform in AML with
         <em>
          U2AF1
         </em>
         mutations [
         <a href="#rid52">
          52,53
         </a>
         ]. IRAK4-L interacts with MyD88 to facilitate assembly of the myddosome complex and maximally activate NF-kB and MAPK. IRAK4-L was shown to be essential for leukemic cell function, and inhibition of IRAK4-L suppressed leukemic growth, particularly in AML cells with higher expression of the
         <em>
          IRAK4-L
         </em>
         isoform. Early phase trials of IRAK-4 inhibitors in MDS and AML have been initiated.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CHROMOSOMAL TRANSLOCATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chromosomal translocations are common in AML. They can affect the cell by one of two mechanisms [
         <a href="#rid54">
          54
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juxtaposition of an intact transcription unit from one chromosome to an enhancer element from a gene on another chromosome. As an example, in t(14;18), the
         <em>
          BCL-2
         </em>
         gene translocates into the immunoglobulin heavy chain (
         <em>
          IgH
         </em>
         ) locus, leading to the inappropriate expression of a normal BCL-2 gene product. (See
         <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">
          "Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Cytogenetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Formation of chimeric fusion proteins. Chromosomal translocations can disrupt two different genes within their coding sequences, leading to the creation of a chimeric protein. For example, the t(9;22) in CML results in the formation of a chimeric
         <em>
          BCR/ABL1
         </em>
         fusion protein. (See
         <a class="medical medical_review" href="/z/d/html/4487.html" rel="external">
          "Cellular and molecular biology of chronic myeloid leukemia", section on 'The BCR-ABL1 fusion protein'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In AML, the vast majority of chromosomal translocations result in the generation of chimeric fusion genes that are never expressed in wild type cells. Characterization of the genes involved in these translocations has led to the elucidation of many transcriptional regulatory pathways in hematopoiesis [
         <a href="#rid55">
          55-58
         </a>
         ]. For example, the alpha and beta subunits of core-binding factor (CBF) have been found to be required for definitive hematopoiesis; both of these subunits are involved in chromosomal translocations in AML.
        </p>
        <p>
         The involvement in chromosomal translocations of several other classes of transcription factors has been recognized, including those that contain zinc fingers, ring fingers, leucine zippers, basic helix-loop-helix motifs, and ETS domains [
         <a href="#rid59">
          59
         </a>
         ]. Homologues of these transcription factors have been well characterized in animal models such as
         <em>
          Drosophila
         </em>
         , including the RUNX1 (AML1) homologue "runt," and the KMT2A (MLL) homologue "trithorax." Several other proteins with well-defined hematopoietic functions have been recognized at chromosomal translocation breakpoints, including retinoic acid receptors and Hox genes. However, structural proteins that do not appear to be specific to myeloid cells have also been identified, including members of the nuclear pore complex and nucleolar phosphoproteins. The functions of many other genes involved in chromosomal translocations remain to be elucidated.
        </p>
        <p>
         Many genes are capable of participating in translocations that involve multiple alternative partner genes. As an example,
         <em>
          KMT2A
         </em>
         (
         <em>
          MLL)
         </em>
         forms chimeric fusion genes with &gt;80 known partners. These various fusions provide an opportunity to contrast the contributions of each component of the fusion gene and thus dissect the motifs within these genes that are critical to tumorigenesis. The fusion of nucleophosmin (
         <em>
          NPM
         </em>
         ) to
         <em>
          ALK
         </em>
         is a frequent recurring abnormality in anaplastic large cell lymphoma.
         <em>
          NPM
         </em>
         also fuses to
         <em>
          RARalpha
         </em>
         in acute promyelocytic leukemia and to
         <em>
          MLF1
         </em>
         in other subtypes of AML. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         In the following sections, we will discuss specific fusion genes in the context of families of fusions that share common features. The recurring involvement of the same genes in multiple different translocations has two important implications:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The genomic structure of these genes may contain "hot spots" for chromosomal breakage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disruption of the pathways regulated by these genes results in malignant transformation, rather than cell death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Involvement of core binding factor
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chromosomal aberrations in AML commonly involve subunits of the core-binding factor (CBF) group of transcription factors [
         <a href="#rid60">
          60,61
         </a>
         ]. Members of the CBF group function as heterodimeric complexes regulating diverse target genes involved in tissue differentiation [
         <a href="#rid62">
          62
         </a>
         ]. CBF factors consist of an alpha subunit that binds DNA, and a beta subunit that does not bind DNA directly but enhances binding by the alpha subunit. Three alpha subunits have been identified: RUNX1 (AML1/CBFA2/PEBP2aB), RUNX2 (AML3/CBFA1/PEBP2aA), and RUNX3 (AML2/CBFA3/PEBP2aC). As will be described below, both the alpha and beta subunits of CBF are disrupted in common subtypes of AML and form chimeric fusion transcripts with genes not normally expressed in hematopoietic cells [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         In hematopoietic cells, CBF binding sites have been observed in genes specific to both the lymphoid lineage (T-cell receptor enhancers,
         <em>
          CD3epsilon
         </em>
         , and
         <em>
          LCK
         </em>
         proximal promoter) and myeloid lineage (M-CSF receptor,
         <em>
          IL-3, GM-CSF
         </em>
         , myeloperoxidase, granzyme B, and neutrophil elastase) [
         <a href="#rid55">
          55,64
         </a>
         ].
        </p>
        <p>
         The RUNX1 (AML1) subunit has been studied extensively in hematopoiesis. Multiple splice variants have been identified; AML1B contains the runt domain and a transactivation domain, whereas AML1A lacks the transactivation domain [
         <a href="#rid65">
          65
         </a>
         ]. Disruption of
         <em>
          RUNX1
         </em>
         by gene targeting in embryonic stem cells results in embryonic lethality due to an absence of fetal liver hematopoiesis and to central nervous system hemorrhage [
         <a href="#rid66">
          66
         </a>
         ]. The knockout of
         <em>
          CBFbeta
         </em>
         results in a similar phenotype, indicating that both the alpha and beta subunits of CBF are essential for definitive but not primitive hematopoiesis [
         <a href="#rid60">
          60,67
         </a>
         ]. The role of CBF in later stages of hematopoietic differentiation is not yet clear.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Familial AML
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormalities in several genes are known to cause inherited forms of myelodysplastic syndrome (MDS) or acute leukemia that can present throughout the lifespan. These include abnormalities in
         <em>
          RUNX1, ANKRD26, CEBPA, GATA2, TERC, TERT, SRP72, PAX5, SH2B3,
         </em>
         and
         <em>
          TP53
         </em>
         . These are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          AML and MDS and myeloproliferative neoplasms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Point mutations of RUNX1 (
         <em>
          AML1
         </em>
         ) have been infrequently reported in de novo AML or MDS, at incidences varying from zero to 12 percent [
         <a href="#rid68">
          68-70
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 132 patients with primary MDS, the presence of these mutations was associated with a significantly higher frequency of chromosome 7/7q deletion as well as shortened overall survival [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study from Japan,
         <em>
          RUNX1
         </em>
         (
         <em>
          AML1)
         </em>
         mutations were found in 6 of 13 Atom-bomb survivors who developed MDS, and in 5 of 13 patients who developed AML/MDS following alkylating agent treatment with or without supplementary radiation [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 18 patients with myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia, primary myelofibrosis) who progressed from chronic phase (CP) to acute leukemia, point mutations of
         <em>
          RUNX1
         </em>
         were detected in five at the time of leukemic transformation but not while they were still in CP [
         <a href="#rid71">
          71
         </a>
         ]. Consistent with the leukemogenic potential of
         <em>
          RUNX1
         </em>
         point mutations, when the
         <em>
          AML1D171N
         </em>
         mutation was transduced into CD34+ cells from patients in the CP of MPNs, this resulted in proliferation of immature myeloid cells, enhanced self-renewal capacity, and proliferation of primitive progenitors.
        </p>
        <p>
        </p>
        <p>
         Abnormalities in RUNX1 are also seen in patients with familial platelet disorder with propensity to myeloid malignancies. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial platelet disorder with propensity to myeloid malignancies (FPD)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Cooperating mutations in AML
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(8;21)(q22;q22) is associated with the FAB-M2 subtype of AML  (
         <a class="graphic graphic_picture graphicRef80200" href="/z/d/graphic/80200.html" rel="external">
          picture 1
         </a>
         ), and was the first recurring chromosomal translocation in AML to be identified [
         <a href="#rid72">
          72
         </a>
         ]. The clinical and morphologic correlations of this subtype of AML include a high propensity to develop extramedullary collections of leukemic blasts (granulocytic sarcomas). Another hallmark of t(8;21) leukemia is the relatively high rate of responsiveness to chemotherapy, particularly to high dose Ara-C [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Leukemic myeloblasts in this subtype have a characteristic morphology, including prominent Auer rods, large cytoplasmic granules, and vacuoles. When the characteristic histologic appearance of these cells is identified in AML blasts that do not contain a t(8;21), the
         <em>
          RUNX1/RUNX1T1
         </em>
         (
         <em>
          ETO)
         </em>
         fusion can be identified by polymerase chain reaction techniques, indicating that the formation of the molecular fusion is responsible for the morphologic and clinical features of this subtype of AML [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         In t(8;21),
         <em>
          RUNX1
         </em>
         fuses to the
         <em>
          RUNX1T1
         </em>
         (
         <em>
          ETO
         </em>
         ) gene on the der(8) chromosome to form a chimeric fusion protein [
         <a href="#rid75">
          75
         </a>
         ]. The chimeric protein fuses the N-terminus of
         <em>
          RUNX1
         </em>
         including the runt homology domain, but excluding the transactivation domain, to nearly all of
         <em>
          RUNX1T1
         </em>
         . The
         <em>
          RUNX1
         </em>
         /
         <em>
          RUNX1T1
         </em>
         fusion gene has pleiotropic effects in reporter gene assays as it appears to repress several RUNX1 target genes [
         <a href="#rid76">
          76,77
         </a>
         ], but to activate the M-CSF receptor promoter [
         <a href="#rid78">
          78,79
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8380.html" rel="external">
          "Regulation of myelopoiesis", section on 'Transcription factors'
         </a>
         .)
        </p>
        <p>
         By engineering a "knock-in" of the
         <em>
          RUNX1T1
         </em>
         cDNA into the murine
         <em>
          RUNX1
         </em>
         locus, a mouse model of t(8;21) has been generated. These mice exhibit a mid-gestation embryonic lethality with an absence of fetal liver hematopoiesis and central nervous system hemorrhage that is similar to the
         <em>
          RUNX1
         </em>
         and
         <em>
          CBFbeta
         </em>
         knockout mice [
         <a href="#rid80">
          80
         </a>
         ]. This result suggests that the
         <em>
          RUNX1/RUNX1T1
         </em>
         fusion gene can act as a dominant negative of normal RUNX1 function.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          RUNX1/EAP, MDS1, EVI1 in t(3;21)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(3;21)(q26;q22) has been observed in the blast crisis of CML and therapy-related MDS and AML [
         <a href="#rid81">
          81
         </a>
         ]. The
         <em>
          RUNX1
         </em>
         (
         <em>
          AML1
         </em>
         ) gene has been found to be rearranged in these cases, leading to the formation of alternative fusion transcripts involving the
         <em>
          EAP, MDS1,
         </em>
         and
         <em>
          EVI1
         </em>
         genes [
         <a href="#rid82">
          82,83
         </a>
         ]. These fusions contain the N-terminus of
         <em>
          RUNX1
         </em>
         , including its runt homology domain, fused to alternative C-terminal sequences derived from partner genes on 3q26.
         <em>
          EVI1
         </em>
         is also involved in the inv(3)(q21q26) and t(3;3)(q21;q26) in AML [
         <a href="#rid84">
          84
         </a>
         ]. However, the consequence of these chromosome aberrations is the inappropriate expression of the
         <em>
          EVI1
         </em>
         transcription unit, whereas in the t(3;21),
         <em>
          EVI1
         </em>
         participates in the formation of a fusion gene with
         <em>
          RUNX1
         </em>
         . Sequences from another transcription unit,
         <em>
          MDS1
         </em>
         , are also observed in t(3;21). Although mapping data indicate that the exons of
         <em>
          MDS1
         </em>
         and
         <em>
          EVI1
         </em>
         are separated by several hundred kilobases, they have been found to be spliced together not only in cases with the t(3;21), but also in normal tissues. The
         <em>
          RUNX1-MDS1
         </em>
         fusion has been shown to transform the Rat1A fibroblast cell line [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          TEL(ETV6) and RUNX1 in t(12;21)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          RUNX1
         </em>
         (
         <em>
          AML1
         </em>
         ) is involved in the t(12;21)(p13;q22), resulting in the generation of a chimeric protein with the TEL(ETV6) gene [
         <a href="#rid86">
          86
         </a>
         ]. The t(12;21) fusion is observed commonly in pre-B-cell ALL. The
         <em>
          TEL
         </em>
         (ETV6) gene was originally cloned from a t(5;12)(q33;p13) in CMML where it fuses to the
         <em>
          PDGFRbeta
         </em>
         gene and it has also been found to fuse to the
         <em>
          ABL1
         </em>
         gene in t(12;22) in AML [
         <a href="#rid87">
          87,88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          CBFb/MYH11 in inv(16) and t(16;16)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The inv(16)(p13q22) and t(16;16)(p13;q22) are observed primarily in the FAB-M4Eo subtype of AML  (
         <a class="graphic graphic_picture graphicRef71045" href="/z/d/graphic/71045.html" rel="external">
          picture 2
         </a>
         ). These patients, similar to those with the t(8;21), have a relatively good prognosis and a high likelihood to respond to high dose cytosine arabinoside-containing chemotherapy regimens [
         <a href="#rid89">
          89
         </a>
         ]. The
         <em>
          CBFbeta
         </em>
         subunit located at 16q22 is disrupted as a result of either the chromosomal inversion or translocation, leading to the formation of a fusion transcript with the gene for smooth muscle myosin heavy chain,
         <strong>
          MYH11
         </strong>
         , located at 16p13 [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         A mouse model for inv(16) leukemia has been generated through a "knock-in" approach [
         <a href="#rid91">
          91
         </a>
         ]. These mice exhibit a mid-gestation embryonic lethality, an absence of fetal liver hematopoiesis, and central nervous system hemorrhage. The chimeric mice generated from embryonic stem cells containing the
         <em>
          CBFb
         </em>
         /
         <em>
          MYH11
         </em>
         fusion did not develop leukemia. However, there was no contribution by the embryonic stem cells to hematopoiesis. Thus, a striking similarity has been observed for the knockouts of
         <em>
          RUNX1
         </em>
         (
         <em>
          AML1)
         </em>
         and
         <em>
          CBFbeta
         </em>
         , as well as the
         <em>
          RUNX1
         </em>
         /
         <em>
          RUNX1T1
         </em>
         and
         <em>
          CBFb
         </em>
         /
         <em>
          MYH11
         </em>
         "knock-in" mice. This convergence in phenotypes from seemingly disparate gene targeting experiments indicates that
         <em>
          RUNX1
         </em>
         and
         <em>
          CBFbeta
         </em>
         are both essential for definitive hematopoiesis, and that both are required for the function of the CBF heterodimer.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Involvement of the KMT2A (MLL) locus
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mixed lineage leukemia gene,
         <em>
          KMT2A
         </em>
         (also known as
         <em>
          MLL
         </em>
         ), located at chromosome band 11q23, is frequently involved in translocations in both AML and ALL and is associated with a poor prognosis. Translocations involving 11q23 are the single most common cytogenetic abnormality in infants with acute leukemia, regardless of phenotype, and occur in approximately 70 to 80 percent of cases. 11q23 translocations are also observed frequently in therapy-related leukemias in patients who have previously been treated with drugs that inhibit topoisomerase II, especially the epipodophyllotoxins. This syndrome differs from the therapy-related myeloid leukemias that occur in patients exposed to alkylating agents, which are commonly associated with deletional events on chromosomes 5 and 7. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 'Therapy-related myeloid neoplasms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Partner chromosomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         There were at least 121 different partner loci involved in recurring reciprocal 11q23 translocations in a molecular analysis of 1590
         <em>
          KMT2A
         </em>
         (
         <em>
          MLL
         </em>
         )-rearranged biopsy samples from adults and children with AML and ALL with
         <em>
          KMT2A
         </em>
         gene rearrangements [
         <a href="#rid92">
          92-96
         </a>
         ]. This exceeds the number of known translocations affecting the immunoglobulin loci, suggesting that the 11q23 breakpoint region may contain genomically unstable sequences leading to recombination events.
        </p>
        <p>
         The chromosomal partners in 11q23 translocations are usually lineage specific. In AML, t(9;11)(p22;q23), t(11;19)(q23;p13.1) and t(6;11)(q27;q23) are the most common, and in ALL, t(4;11)(q21;q23) and t(11;19)(q23;p13.3) occur predominantly. Translocations at 11q23 have been observed in several FAB subtypes, but occur most commonly in the FAB-M4 myelomonocytic and FAB-M5 monoblastic leukemias [
         <a href="#rid93">
          93,97,98
         </a>
         ]. Myeloid leukemias with 11q23 translocations often coexpress lymphoid markers, whereas 11q23 lymphoid leukemias often express myeloid or monocytoid markers in addition to B-cell markers. These observations suggest that rearrangements of
         <em>
          KMT2A
         </em>
         may affect a pluripotent stem cell or, alternatively, that disruption of
         <em>
          KMT2A
         </em>
         may affect a common differentiation pathway shared by lymphoid and myeloid progenitor cells.
        </p>
        <p>
         In a subset of patients with AML and either trisomy 11 or a normal karyotype, a unique pattern of rearrangement of the
         <em>
          KMT2A
         </em>
         gene has been observed. As in the translocations that affect
         <em>
          KMT2A
         </em>
         , a fusion occurs involving one of the exons in its breakpoint cluster region. However, rather than fusing to a partner gene, the fusion is to 5' sequences from
         <em>
          KMT2A
         </em>
         itself [
         <a href="#rid99">
          99,100
         </a>
         ]. These partial duplications of
         <em>
          KMT2A
         </em>
         appear to occur primarily in older patients and are infrequent in childhood and therapy-related leukemias. The morphology of the leukemias also differs in that the partial duplication patients usually are classified as FAB M1 or M2, rather than the M4 or M5 typically observed in cases with
         <em>
          KMT2A
         </em>
         translocations.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          KMT2A
         </em>
         (
         <em>
          MLL
         </em>
         ) gene was isolated from the 11q23 breakpoint by several groups and has been referred to by other names including
         <em>
          HRX, ALL-1,
         </em>
         and
         <em>
          Htrx
         </em>
         [
         <a href="#rid101">
          101-104
         </a>
         ].
         <em>
          KMT2A
         </em>
         encodes a large protein (predicted molecular weight of 430 kD) that contains two regions of extensive homology to the Drosophila trithorax gene [
         <a href="#rid105">
          105
         </a>
         ]. KMT2A is a histone methyltransferase that plays a critical role in normal embryonic development and hematopoiesis, mainly regulating transcription via epigenetic mechanisms [
         <a href="#rid106">
          106
         </a>
         ]. Translocations create KMT2A fusion proteins that induce aberrant expression of downstream mediators, including HOXA proteins and myeloid ecotropic viral integration site 1 (
         <em>
          MEIS1
         </em>
         ) [
         <a href="#rid107">
          107-110
         </a>
         ]. KMT2A fusion proteins also appear to deregulate the RNA polymerase II elongation factor, thereby disrupting checkpoints for transcription elongation [
         <a href="#rid111">
          111,112
         </a>
         ]. Both Menin and lens epithelium-derived growth factor (LEDGF) appear to be key elements in the interaction between the KMT2A histone methyltransferase and the nonmethylated CpG DNA to which it binds [
         <a href="#rid113">
          113
         </a>
         ]. A selective inhibitor of the KMT2A-Menin interaction was shown to inhibit growth of cell lines harboring KMT2A fusions and prolong survival in mouse models of KMT2A leukemia [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         Several animal and cell culture models of KMT2A leukemia have been developed. To create an KMT2A-AF9 "knock-in" mouse model of 11q23 leukemias, the AF9 cDNA was targeted into the murine
         <em>
          KMT2A
         </em>
         locus by homologous recombination in embryonic stem cells [
         <a href="#rid115">
          115
         </a>
         ]. The chimeric mice generated from these embryonic stem cells all developed acute myeloid leukemia within 6 to 9 months. Retroviral bone marrow infection has been used to express another 11q23 fusion gene,
         <em>
          KMT2A-ENL
         </em>
         , in hematopoietic cells [
         <a href="#rid116">
          116
         </a>
         ]. After transplantation of
         <em>
          KMT2A-ENL
         </em>
         transduced bone marrow, recipient mice developed acute myeloid leukemia. Retroviral transduction/transplantation models using several
         <em>
          KMT2A
         </em>
         partner genes have been established [
         <a href="#rid117">
          117,118
         </a>
         ]. These models have established the proof of principle that the expression of
         <em>
          KMT2A
         </em>
         fusion genes contributes to leukemogenesis, and that the
         <em>
          KMT2A
         </em>
         partner genes are essential to this process [
         <a href="#rid94">
          94,119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H91419960">
         <span class="h2">
          Involvement of the retinoic acid receptor
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cytogenetic hallmark of acute promyelocytic leukemia (APL, FAB-M3), is a translocation involving the retinoic acid receptor-alpha (
         <em>
          RARalpha
         </em>
         ) locus on chromosome 17 [
         <a href="#rid120">
          120
         </a>
         ]. The vast majority of these cases contain a t(15;17)(q22;q11-12), although several variant translocations involving
         <em>
          RARalpha
         </em>
         have been identified. These include
         <em>
          PLZF
         </em>
         in t(11;17)(q23;q11-12) and
         <em>
          NPM
         </em>
         in t(5;17)(q35;q11-12). These translocations lead to the formation of chimeric fusion transcripts from each of the derivative chromosomes. The pathobiology of APL is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4523.html" rel="external">
          "Molecular biology of acute promyelocytic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Other fusion genes in AML
         </span>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          DEK/CAN in t(6;9) and SET-CAN
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(6;9)(p23;q34) is observed usually in the M2 and M4 subtypes of AML but has also been identified in the M1 subtype and MDS. This translocation is associated with a younger age and a poor prognosis. The
         <em>
          CAN
         </em>
         gene was also found to be rearranged in a patient with acute undifferentiated leukemia and a normal karyotype. A chimeric transcript containing an alternative
         <em>
          CAN
         </em>
         partner gene, named
         <em>
          SET
         </em>
         , was isolated in this case [
         <a href="#rid121">
          121
         </a>
         ]. The
         <em>
          SET
         </em>
         gene was also localized to 9q34, suggesting that this fusion results from an inversion of chromosome 9 or a cryptic translocation.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          TLS/FUS/ERG and t(16;21)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(16;21)(p11;q22) has been observed in several FAB subtypes of AML, blast crisis of CML, and MDS [
         <a href="#rid122">
          122,123
         </a>
         ]. In this translocation, the
         <em>
          TLS/FUS
         </em>
         gene at 16p11 fuses to the
         <em>
          ERG
         </em>
         gene at 21q22 to generate a chimeric protein. Both
         <em>
          TLS/FUS
         </em>
         and
         <em>
          ERG
         </em>
         are involved in chromosomal translocations with other partner genes in sarcomas [
         <a href="#rid124">
          124-126
         </a>
         ]. The striking similarity of the
         <em>
          TLS/FUS/ERG
         </em>
         fusion gene in AML to the sarcoma associated fusion genes suggests that disruption of a common differentiation pathway may lead to transformation in multiple cell types.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          NPM/MLF1 in t(3;5)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(3;5)(q25.1;q35) has been observed in several FAB subtypes of AML, especially in M6 and MDS [
         <a href="#rid127">
          127
         </a>
         ]. The
         <em>
          NPM
         </em>
         gene at 5q35 was found to be rearranged in patients with this translocation, resulting in the formation of a fusion gene with the
         <em>
          MLF1
         </em>
         (myelodysplasia-myeloid leukemia factor 1) gene at 3q25.1. Previously, the involvement of
         <em>
          NPM
         </em>
         had been identified in the t(2;5)(p23;q35) in anaplastic large cell lymphoma, where it fuses to the
         <em>
          ALK
         </em>
         gene [
         <a href="#rid128">
          128
         </a>
         ].
         <em>
          NPM
         </em>
         is also rearranged in the t(5;17)(q35;q21) in APL, where it fuses to
         <em>
          RARalpha
         </em>
         .
        </p>
        <p>
         The MLF1 protein normally localizes to the cytoplasm, whereas in leukemia cells with t(3;5), the
         <em>
          NPM-MLF1
         </em>
         fusion protein is observed primarily in nucleoli. The involvement of
         <em>
          NPM
         </em>
         in chromosome translocations involving three different partner genes, resulting in three discrete types of hematologic malignancies, suggests that NPM plays an important role in normal hematopoietic differentiation.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          EVI1 in inv(3) and t(3;3)
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          EVI1
         </em>
         (Ecotropic Virus Integration 1) was initially cloned as the gene at a common site of retroviral integration in murine myeloid leukemia. The
         <em>
          EVI1
         </em>
         gene is normally expressed only in kidney and ovary. In mice, the retroviral integration at the murine
         <em>
          Evi1
         </em>
         locus leads to its inappropriate expression in hematopoietic cells. A similar phenomenon occurs in human AML with inv(3)(q21q26) and t(3;3)(q21;q26) [
         <a href="#rid129">
          129
         </a>
         ]. As a result of these cytogenetic aberrations, the
         <em>
          EVI1
         </em>
         gene is juxtaposed to enhancer elements of the Ribophorin gene leading to inappropriate activation of the
         <em>
          EVI1
         </em>
         transcription unit, a component of the complex fusion transcripts that involve the
         <em>
          RUNX1
         </em>
         gene in t(3;21).
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          MOZ/CBP in t(8;16)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(8;16)(p11;p13) has been recognized in the M4 and M5 subtypes of AML that exhibit a characteristic erythrophagocytosis [
         <a href="#rid130">
          130
         </a>
         ]. This translocation has been observed in both de novo and therapy-related leukemias. Several variant translocations involving 8p11 have been recognized in monocytic leukemias with erythrophagocytosis, but the genes involved in these translocations have not yet been cloned.
         <em>
          CBP
         </em>
         is also involved with a fusion to
         <em>
          KMT2A
         </em>
         in t(11;16)(q23;p13) [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          CALM/AF10 in t(10;11)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(10;11)(p13;q14) has been recognized in both ALL and AML. In AML, the cases are primarily of the M0 and M1 subtypes [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          NUP98/HOXA9 in t(7;11) and NUP98/DDX10 in inv(11)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The t(7;11)(p15;p15) is observed in the M2 and M4 subtypes of AML and CML. The
         <em>
          HOXA9
         </em>
         gene was identified at the 7p15 breakpoint and the
         <em>
          NUP98
         </em>
         gene at the 11p15 break [
         <a href="#rid133">
          133
         </a>
         ]. In BXH-2 mice, the Hoxa9 gene has been implicated in myeloid leukemia as a result of its activation via proviral insertion.
         <em>
          NUP98
         </em>
         has been found to be involved in the inv(11)(p15q22) in AML. This cytogenetic aberration has been recognized in both de novo and therapy-related MDS and AML.
        </p>
        <p>
         In addition, a t(10;11)(q23;p15) translocation involving the
         <em>
          NUP98
         </em>
         gene at 11q15 and the hematopoietically expressed homeobox gene (
         <em>
          HHEX
         </em>
         ) at 10q23 has been implicated in AML [
         <a href="#rid134">
          134
         </a>
         ]. Other cases of AML have been identified that demonstrate a
         <em>
          NUP98-KMT2A
         </em>
         fusion protein with low levels of
         <em>
          HOXA
         </em>
         gene expression [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          ANIMAL MODELS OF AML
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several examples of naturally occurring animal models of AML that are caused by retroviruses via one of two mechanisms. The retrovirus can:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Encode for an oncogene that leads to transformation,
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It can inappropriately activate the expression of a gene adjacent to its integration site
        </p>
        <p>
        </p>
        <p>
         The characterization of these processes has revealed a number of genes critical to normal hematopoiesis and myeloid leukemias. These animal models have also demonstrated the multistage nature of the evolution of leukemia.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Myb leukemias
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          v-Myb
         </em>
         gene is involved in two different avian retroviruses that induce leukemia in chickens. The
         <em>
          v-Myb
         </em>
         gene was originally identified as the transforming element in the avian myeloblastosis virus (AMV). In the E26 retrovirus, a fusion gene consisting of
         <em>
          gag, v-Myb,
         </em>
         and
         <em>
          v-Ets
         </em>
         has been identified [
         <a href="#rid135">
          135
         </a>
         ]. The formation of a fusion gene containing sequences of two transcription factors is reminiscent of the fusions that result from chromosomal translocations in human acute leukemia. In chickens, AMV causes monoblastic leukemias and transforms only myelomonocytic cells in vitro, whereas E26 induces erythroleukemias, but is capable of transforming myeloid, erythroid, and megakaryocytic lineages in vitro [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p>
         <em>
          C-Myb
         </em>
         , the normal cellular counterpart of
         <em>
          v-Myb
         </em>
         , is essential for definitive hematopoiesis [
         <a href="#rid137">
          137
         </a>
         ]. Promonocytic leukemias have been induced by priming mice with intraperitoneal injections of pristane, followed by infection with the Moloney murine leukemia virus [
         <a href="#rid138">
          138
         </a>
         ]. The majority of the mice that develop leukemia have undergone insertional mutagenesis at the
         <em>
          c-Myb
         </em>
         locus [
         <a href="#rid139">
          139
         </a>
         ]. The role of pristane is unknown, but it appears to promote leukemogenesis by mediating an inflammatory response. At this time, there is no evidence for the rearrangement of c-Myb in human leukemias.
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h2">
          Friend virus/SFFV erythroleukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         The erythroleukemia induced by infection with the Friend viral complex is the culmination of a three step process that has become a paradigm for multistage neoplastic transformation [
         <a href="#rid140">
          140
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyclonal proliferation induced by a cytokine
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inactivation of a tumor suppressor gene
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oncogenic activation of a gene involved in normal hematopoiesis
        </p>
        <p>
        </p>
        <p>
         Infection of susceptible mice with the Friend murine leukemia virus/spleen focus-forming virus (SFFV) complex induces a polyclonal proliferation of erythroid progenitors within 48 hours. This expansion of erythroid precursors is secondary to the
         <em>
          SFFV
         </em>
         envelope gene product, the gp55 glycoprotein, which has the capacity to bind and activate the erythropoietin receptor. These erythroid cells are not transformed and retain the ability to undergo terminal differentiation.
        </p>
        <p>
         After approximately two weeks, a clonal population of transformed erythroblasts emerges which depends on two additional independent genetic events. One of these is the inactivation of the p53 tumor suppressor gene by deletion, mutation, or proviral insertion [
         <a href="#rid141">
          141,142
         </a>
         ]. In addition, the activation of either the
         <em>
          PU.1
         </em>
         gene, also referred to as
         <em>
          Spi-1
         </em>
         (SFFV proviral integration 1), or the
         <em>
          Fli-1
         </em>
         gene occur as a result of proviral integration adjacent to these loci [
         <a href="#rid143">
          143,144
         </a>
         ].
         <em>
          PU.1
         </em>
         and
         <em>
          Fli-1
         </em>
         are members of the ETS family of transcription factors;
         <em>
          PU.1
         </em>
         is essential for both myeloid and lymphoid development [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h2">
          BXH-2 leukemias
         </span>
         <span class="headingEndMark">
          —
         </span>
         BXH-2 mice are derived from a cross of C57BL/6J and C3H/He mice. Although the parental strains have a low incidence of leukemia, more than 95 percent of BXH-2 mice develop myeloid leukemia by one year of age, caused by expression of a horizontally transmitted Ecotropic murine leukemia virus [
         <a href="#rid146">
          146
         </a>
         ]. These retroviruses induce leukemia by insertional activation or mutation of proto-oncogenes adjacent to the viral integration site. One of the most frequent viral integration sites is
         <em>
          Evi-2
         </em>
         (Ecotropic viral integration site 2), localized to a large intron within the
         <em>
          Nf1
         </em>
         tumor suppressor gene [
         <a href="#rid147">
          147
         </a>
         ]. The consequence of this integration event is the disruption of the normal expression of
         <em>
          Nf1
         </em>
         in the affected mice.
        </p>
        <p>
         In humans, the neurofibromatosis type I autosomal dominant disorder is caused by mutation of the
         <em>
          NF1
         </em>
         gene [
         <a href="#rid148">
          148
         </a>
         ]. In addition to neurofibromas, patients have an increased risk of developing several types of solid tumors and malignant myeloid disorders, especially juvenile chronic myeloid leukemia (JCML) and the monosomy 7 syndrome [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
         Mice heterozygous for the
         <em>
          Nf1
         </em>
         allele develop myeloid leukemia with loss of the wild type allele, indicating that Nf1 acts as a tumor suppressor [
         <a href="#rid150">
          150
         </a>
         ]. In JCML patients without neurofibromatosis, activating
         <em>
          RAS
         </em>
         mutations are frequently identified. The consequence of either the disruption of
         <em>
          NF1
         </em>
         or the activation of
         <em>
          RAS
         </em>
         has been shown to be an inability to negatively regulate GM-CSF signaling in hematopoietic cells [
         <a href="#rid151">
          151,152
         </a>
         ].
        </p>
        <p>
         Because viral integration within the
         <em>
          Nf1
         </em>
         gene has been observed in only 15 percent of BXH-2 mice, the identification of additional mutations within other genes associated with myeloid leukemias has been pursued. A proviral tagging approach has been used to identify additional viral integration sites that alter the expression of three genes,
         <em>
          Hoxa7, Hoxa9,
         </em>
         and
         <em>
          Meis-1
         </em>
         [
         <a href="#rid153">
          153,154
         </a>
         ]. The
         <em>
          HOXA9
         </em>
         gene is involved in t(7;11)(p15;p15) in AML, resulting in the formation of a fusion gene with NUP98. HOX gene overexpression has also been demonstrated in mice with acquired nucleophosmin mutations that result in the cytoplasmic dislocation of nucleophosmin (ie, NPM1c) [
         <a href="#rid155">
          155
         </a>
         ].
         <em>
          PBX1
         </em>
         is involved in t(1;19) in ALL, where it fuses to the
         <em>
          E2A
         </em>
         gene. This underscores a recurring theme of the involvement of similar families of genes in both human and spontaneous animal models of AML.
        </p>
        <p class="headingAnchor" id="H12775108">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/681.html" rel="external">
          "Patient education: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H91418851">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute myeloid leukemia (AML)
         </strong>
         – AML develops as the consequence of genetic changes in a hematopoietic precursor cell that alters normal growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and blood. These aberrant cells can divide and proliferate, but they cannot differentiate normally into mature, fully functional hematopoietic cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognostic significance
         </strong>
         – Many of the chromosomal abnormalities and gene mutations are associated with prognosis in AML  (
         <a class="graphic graphic_table graphicRef80216" href="/z/d/graphic/80216.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef60295" href="/z/d/graphic/60295.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mutations of oncogenes and tumor suppressors
         </strong>
         – Cases of AML may demonstrate mutations in oncogenes (eg,
         <em>
          NRAS, FLT3
         </em>
         ) and/or loss of tumor suppressor genes (eg,
         <em>
          TP53, WT1
         </em>
         [Wilms tumor suppressor gene]). (See
         <a class="local">
          'Gene mutations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chromosomal translocations
         </strong>
         – Many hematologic malignancies are associated with specific chromosomal translocations that generate chimeric fusion genes that are never expressed in wild type cells. Chromosomal aberrations in AML commonly involve transcription factors that regulate hematopoiesis. (See
         <a class="local">
          'Chromosomal translocations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Core binding factor abnormalities
         </strong>
         – The chromosomal aberrations t(8;21)(q22;q22) and the inv(16)(p13q22) in AML involve subunits of the core-binding factor (CBF) group of transcription factors. Members of the CBF group function as heterodimeric complexes regulating diverse target genes involved in tissue differentiation. (See
         <a class="local">
          'Involvement of core binding factor'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          KMT2A (MLL)
         </strong>
         – The mixed lineage leukemia gene,
         <em>
          KMT2A
         </em>
         (
         <em>
          MLL
         </em>
         ), located at chromosome band 11q23, is frequently involved in translocations in AML with different partner chromosomes. KMT2A is a histone methyltransferase that plays a critical role in normal embryonic development and hematopoiesis, mainly regulating transcription via epigenetic mechanisms. Translocations involving
         <em>
          KMT2A
         </em>
         result in
         <em>
          KMT2A
         </em>
         fusion proteins that induce the aberrant expression of downstream mediators. (See
         <a class="local">
          'Involvement of the KMT2A (MLL) locus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute promyelocytic leukemia (APL)
         </strong>
         – The cytogenetic hallmark of APL is a translocation involving the retinoic acid receptor-alpha (
         <em>
          RARA
         </em>
         ) locus on chromosome 17. These translocations lead to the formation of chimeric fusion transcripts from each of the derivative chromosomes. The pathobiology of acute promyelocytic leukemia is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4523.html" rel="external">
          "Molecular biology of acute promyelocytic leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009; 106:12950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radtke I, Mullighan CG, Ishii M, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 2009; 106:12944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 2016; 127:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coombs CC, Tallman MS, Levine RL. Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol 2016; 13:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci G, Yan P, Maharry K, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 2014; 32:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung N, Fung TK, Zeisig BB, et al. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. Cancer Cell 2016; 29:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118:4509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell 2015; 57:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 2014; 9:1841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boissel N, Nibourel O, Renneville A, et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2011; 117:3696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer 2013; 109:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja H, Bar-Eli M, Arlin Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991; 87:2042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelman Z, Prokocimer M, Peller S, et al. Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 1989; 74:2318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mashal R, Shtalrid M, Talpaz M, et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 1990; 75:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori N, Hidai H, Yokota J, et al. Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia. Leuk Res 1995; 19:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanza C, Gaidano G, Cimino G, et al. p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. Leukemia 1995; 9:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanza C, Gaidano G, Cimino G, et al. Distribution of TP53 mutations among acute leukemias with MLL rearrangements. Genes Chromosomes Cancer 1996; 15:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84:3071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 1990; 61:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994; 70:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 2008; 111:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeleznik-Le NJ, Nucifora G, Rowley JD. The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities. Semin Hematol 1995; 32:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahuja HG, Foti A, Bar-Eli M, Cline MJ. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75:1684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neubauer A, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83:1603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakagawa T, Saitoh S, Imoto S, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor JA, Sandler DP, Bloomfield CD, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lübbert M, Mirro J Jr, Kitchingman G, et al. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu ET, Dodge R, Myer A, et al. De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy. Blood 1995; 86:598a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunetti L, Gundry MC, Goodell MA. New insights into the biology of acute myeloid leukemia with mutated NPM1. Int J Hematol 2019; 110:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pellagatti A, Armstrong RN, Steeples V, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood 2018; 132:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MA, Choudhary GS, Pellagatti A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol 2019; 21:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawyers CL. Molecular genetics of acute leukaemia. Lancet 1997; 349:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87:4025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112:1751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols J, Nimer SD. Transcription factors, translocations, and leukemia. Blood 1992; 80:2953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996; 87:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000; 18:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodan GA, Harada S. The missing bone. Cell 1997; 89:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003; 21:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Wang Q, Crute BE, et al. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 1993; 13:3324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka T, Tanaka K, Ogawa S, et al. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J 1995; 14:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki K, Yagi H, Bronson RT, et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc Natl Acad Sci U S A 1996; 93:12359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harada H, Harada Y, Tanaka H, et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakao M, Horiike S, Fukushima-Nakase Y, et al. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome. Br J Haematol 2004; 125:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding Y, Harada Y, Imagawa J, et al. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009; 114:5201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield CD, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84:111a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucifora G, Dickstein JI, Torbenson V, et al. Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 1994; 8:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linggi B, Müller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002; 8:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 2003; 101:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhoades KL, Hetherington CJ, Rowley JD, et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci U S A 1996; 93:11895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pabst T, Mueller BU, Harakawa N, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin CC, Cortes J, Barkoh B, et al. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy. Cancer 2006; 106:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucifora G, Birn DJ, Espinosa R 3rd, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 1993; 81:2728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitani K, Ogawa S, Tanaka T, et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994; 13:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzukawa K, Parganas E, Gajjar A, et al. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994; 84:2681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zent CS, Mathieu C, Claxton DF, et al. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A 1996; 93:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995; 92:4917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 1996; 16:4107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu P, Tarlé SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 1993; 261:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996; 87:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basecke J, Whelan JT, Griesinger F, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 2006; 135:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltenbach S, Soler G, Barin C, et al. NUP98-MLL fusion in human acute myeloblastic leukemia. Blood 2010; 116:2332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013; 27:2165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blum W, Mrózek K, Ruppert AS, et al. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2004; 101:1420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jourdan E, Dastugue N. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2005; 103:1316; author reply 1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schichman SA, Canaani E, Croce CM. Self-fusion of the ALL1 gene. A new genetic mechanism for acute leukemia. JAMA 1995; 273:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 1991; 88:10735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gu Y, Nakamura T, Alder H, et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djabali M, Selleri L, Parry P, et al. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1993; 4:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazo AM, Huang DH, Mozer BA, Dawid IB. The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. Proc Natl Acad Sci U S A 1990; 87:2112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009; 113:6061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milne TA, Kim J, Wang GG, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell 2010; 38:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Song J, Milne TA, et al. Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell 2010; 141:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010; 17:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Z, Iwasaki M, Ficara F, et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010; 10:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jin S, Zhao H, Yi Y, et al. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 2010; 120:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell 2019; 36:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corral J, Lavenir I, Impey H, et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996; 85:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16:4226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci U S A 2000; 97:10984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo RT, Lavau C, Du C, et al. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol 2001; 21:5678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMartino JF, Miller T, Ayton PM, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 2000; 96:3887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Thé H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Lindern M, Breems D, van Baal S, et al. Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer 1992; 5:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa H, Shimizu K, Hayashi Y, Ohki M. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 1994; 54:2865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panagopoulos I, Aman P, Fioretos T, et al. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 1994; 11:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panagopoulos I, Höglund M, Mertens F, et al. Fusion of the EWS and CHOP genes in myxoid liposarcoma. Oncogene 1996; 12:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hui CH, Suttle J. Erythrophagocytosis associated with AML-M5 and t(8;16). Br J Haematol 2001; 113:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobulo OM, Borrow J, Tomek R, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 1997; 94:8732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caudell D, Aplan PD. The role of CALM-AF10 gene fusion in acute leukemia. Leukemia 2008; 22:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996; 12:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic D, Gorello P, Liu T, et al. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood 2008; 111:5672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz T, Graf T. Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus. Cell 1991; 66:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graf T, McNagny K, Brady G, Frampton J. Chicken "erythroid" cells transformed by the Gag-Myb-Ets-encoding E26 leukemia virus are multipotent. Cell 1992; 70:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mucenski ML, McLain K, Kier AB, et al. A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 1991; 65:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazarov V, Hilbert D, Wolff L. Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia. Virology 1994; 205:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazarov V, Wolff L. Novel integration sites at the distal 3' end of the c-myb locus in retrovirus-induced promonocytic leukemias. J Virol 1995; 69:3885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-David Y, Bernstein A. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 1991; 66:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munroe DG, Peacock JW, Benchimol S. Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles. Mol Cell Biol 1990; 10:3307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavigueur A, Bernstein A. p53 transgenic mice: accelerated erythroleukemia induction by Friend virus. Oncogene 1991; 6:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau-Gachelin F, Ray D, Mattei MG, et al. The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias. Oncogene 1989; 4:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul R, Schuetze S, Kozak SL, et al. The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J Virol 1991; 65:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994; 265:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buchberg AM, Bedigian HG, Jenkins NA, Copeland NG. Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol Cell Biol 1990; 10:4658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995; 69:5095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho BC, Shaughnessy JD Jr, Largaespada DA, et al. Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas. J Virol 1995; 69:7138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon KM, Watterson J, Johnson P, et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. Blood 1992; 79:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacks T, Shih TS, Schmitt EM, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994; 7:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996; 12:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 1996; 12:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Largaespada DA, Shaughnessy JD Jr, et al. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 1996; 12:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura T, Jenkins NA, Copeland NG. Identification of a new family of Pbx-related homeobox genes. Oncogene 1996; 13:2235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011; 43:470.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4502 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19651600" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acquired copy number alterations in adult acute myeloid leukemia genomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19651601" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23634996" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26660431" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26620272" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Molecular therapy for acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24378410" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26766589" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21067377" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : DNMT3A mutations in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21399634" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20639862" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19474426" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mutation in TET2 in myeloid cancers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21803851" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25601757" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482556" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21596855" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21454467" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23736028" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Functional and cancer genomics of ASXL family members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2040694" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2572286" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1967214" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8551805" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7596184" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824725" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Distribution of TP53 mutations among acute leukemias with MLL rearrangements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186996" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7949179" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9242555" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2154335" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2163761" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9131006" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947106" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8302341" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7620180" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Role of the cyclin-dependent kinase inhibitors in the development of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7684624" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3950675" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1655239" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Two different classes of therapy-related and de-novo acute myeloid leukemia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8707757" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Therapy-related myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11290608" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17965322" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7570064" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The molecular biology of myeloproliferative disorders as revealed by chromosomal abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2183888" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8123851" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1613006" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Molecular genetic aspects of myelodysplastic syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1574246" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2547513" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : ras oncogenes in human cancer: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1433344" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : ras oncogene activation and occupational exposures in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1549347" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8329714" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15659725" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30632059" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : New insights into the biology of acute myeloid leukemia with mutated NPM1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21909114" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Frequent pathway mutations of splicing machinery in myelodysplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29930011" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31011167" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7969446" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Chromosomal translocations in human cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9226149" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Transcription factors, normal myeloid development, and leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9111557" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Molecular genetics of acute leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639758" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The transcriptional control of hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14660751" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1361370" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Transcription factors, translocations, and leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8929538" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11107447" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9182754" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The missing bone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12643014" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : AML1 interconnected pathways of leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497254" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530657" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565077" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8901586" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393679" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15180860" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17910630" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19850737" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795214" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7522291" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391946" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091906" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393465" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876234" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11283671" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054947" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16532439" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8490181" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8313895" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7919381" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8577711" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7761424" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8168137" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8754809" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751631" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8351518" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8929537" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8361504" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12805060" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16965385" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The MLL partial tandem duplication in acute myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20558618" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : NUP98-MLL fusion in human acute myeloblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23628958" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The MLL recombinome of acute leukemias in 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15368330" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15700268" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7837391" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Self-fusion of the ALL1 gene. A new genetic mechanism for acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640834" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1720549" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1423625" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1423624" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8401594" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2107543" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The trithorax gene, a trans-acting regulator of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19289854" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Therapeutic targeting of MLL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20541448" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20541251" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20541477" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20541704" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20844554" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20159561" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20093773" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31821784" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8681380" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9250666" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10995463" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11463848" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090074" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2170850" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1384675" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8187069" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7533529" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503811" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8162068" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8637704" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Fusion of the EWS and CHOP genes in myxoid liposarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8570204" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8122112" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660833" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11442471" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Erythrophagocytosis associated with AML-M5 and t(8;16).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9238046" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094714" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The role of CALM-AF10 gene fusion in acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563754" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18388181" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2070421" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1322247" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Chicken "erythroid" cells transformed by the Gag-Myb-Ets-encoding E26 leukemia virus are multipotent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1709592" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7975249" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Susceptibility and resistance to Moloney murine leukemia virus-induced promonocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7745739" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Novel integration sites at the distal 3' end of the c-myb locus in retrovirus-induced promonocytic leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1889087" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Friend virus-induced erythroleukemia and the multistage nature of cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1694008" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Inactivation of the cellular p53 gene is a common feature of Friend virus-induced erythroleukemia: relationship of inactivation to dominant transforming alleles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1766668" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : p53 transgenic mice: accelerated erythroleukemia induction by Friend virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2594367" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1985210" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8079170" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2167436" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Evi-2, a common integration site involved in murine myeloid leukemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7609078" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7474134" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1536955" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7920653" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563751" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563750" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8563752" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8950991" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Identification of a new family of Pbx-related homeobox genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21441929" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
